C4 Therapeutics(CCCC) - 2025 Q3 - Quarterly Results

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights Completed Equity Of ering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase 1 Multiple Myeloma Data Support Potential Best-in-Class Profile With a 53% Overall Response Rate at the Highest Dose Level (100 µg) and Dif erentiated Safety and Tolerability Profile Entered Into Clin ...